Evidence map›Paper›PMID 30511107›Full record

Trial reportPathology oncology research : POR2019

Combined Treatment with Autologous CIK Cells, Radiotherapy and Chemotherapy in Advanced Cervical Cancer.

Ning Li, Yong-Wei Tian, Yue Xu, Dan-Dan Meng, Ling Gao, Wen-Jie Shen, Zong-Lan Liu, Zhi-Qiao Xu

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Pathology oncology research : POR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Cervical Cancer Immunotherapy: Facts and Hopes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ning LiThe Center of Tumor Diagnosis and Treatment, Kaifeng Central Hospital, No.85 Hedao Street, Longting District, Kaifeng, 475001, Henan, China.
Yong-Wei TianThe Center of Tumor Diagnosis and Treatment, Kaifeng Central Hospital, No.85 Hedao Street, Longting District, Kaifeng, 475001, Henan, China.
Yue XuThe Center of Tumor Diagnosis and Treatment, Kaifeng Central Hospital, No.85 Hedao Street, Longting District, Kaifeng, 475001, Henan, China.
Dan-Dan MengThe Center of Tumor Diagnosis and Treatment, Kaifeng Central Hospital, No.85 Hedao Street, Longting District, Kaifeng, 475001, Henan, China.
Ling GaoThe Center of Tumor Diagnosis and Treatment, Kaifeng Central Hospital, No.85 Hedao Street, Longting District, Kaifeng, 475001, Henan, China.
Wen-Jie ShenThe Department of Statistics, Kaifeng Central Hospital, No.85 Hedao Street, Longting District, Kaifeng, 475001, Henan, China.
Zong-Lan LiuThe Department of Statistics, Kaifeng Central Hospital, No.85 Hedao Street, Longting District, Kaifeng, 475001, Henan, China.
Zhi-Qiao XuThe Center of Tumor Diagnosis and Treatment, Kaifeng Central Hospital, No.85 Hedao Street, Longting District, Kaifeng, 475001, Henan, China. liningkfyy@163.com.
Kaifeng University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the clinical efficacy of autologous cytokine induced killer (CIK) cells transfusion combined with radiochemotherapy in the treatment of advanced cervical cancer. A total of 89 hospitalized patients with advanced cervical cancer were admitted and divided into the treatment group (44 cases, autologous CIK cells transfusion combined with radiochemotherapy) and the control group (45 cases, radiochemotherapy) by a randomized non-blind method. Comparisons of therapeutic efficacies, immune functions, life qualities and survival rates were analyzed between the two groups. The short-term therapeutic efficacy of the treatment group was significantly higher than that of the control group. There was no significant difference in 1, 2 and 3 year survival rates between the two groups. Compared with pre-treatment, levels of CD3

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinomaCarcinoma, AdenosquamousCarcinoma, Small CellCarcinoma, Squamous CellChemoradiotherapyCombined Modality TherapyCytokine-Induced Killer CellsFemaleHumansImmunotherapy, AdoptiveMiddle AgedAdvanced cervical cancerAutologous CIK cellRadiochemotherapy

Identifiers

PMID30511107
OpenAlexW2903421780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.